{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:02Z","timestamp":1791644762768,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10384-022-00906-3","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T03:02:46Z","timestamp":1646190166000},"page":"254-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction"],"prefix":"10.1007","volume":"66","author":[{"given":"Jay Won","family":"Rhim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-4409","authenticated-orcid":false,"given":"Youngsub","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Gyu","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Myung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"906_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ophtha.2012.06.064","volume":"119","author":"GN Foulks","year":"2012","unstructured":"Foulks GN, Nichols KK, Bron AJ, Holland EJ, McDonald MB, Nelson JD. Improving awareness, identification, and management of meibomian gland dysfunction. Ophthalmology. 2012;119:S1-12.","journal-title":"Ophthalmology"},{"key":"906_CR2","doi-asserted-by":"crossref","unstructured":"Suzuki T. Inflamed obstructive meibomian gland dysfunction causes ocular surface inflammation. Invest Ophthalmol Vis Sci 2018;59:Des94-des101.","DOI":"10.1167\/iovs.17-23345"},{"key":"906_CR3","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","volume":"52","author":"JD Nelson","year":"2011","unstructured":"Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52:1930\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"906_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jtos.2019.02.005","volume":"17","author":"D Borchman","year":"2019","unstructured":"Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf. 2019;17:360\u20134.","journal-title":"Ocul Surf"},{"key":"906_CR5","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s10792-020-01489-z","volume":"40","author":"X Wu","year":"2020","unstructured":"Wu X, Chen X, Ma Y, Lin X, Yu X, He S, et al. Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction. Int Ophthalmol. 2020;40:3049\u201358.","journal-title":"Int Ophthalmol"},{"key":"906_CR6","first-page":"1797","volume":"7","author":"J Qiao","year":"2013","unstructured":"Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1797\u2013803.","journal-title":"Clin Ophthalmol"},{"key":"906_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40265-015-0432-8","volume":"75","author":"AR Thode","year":"2015","unstructured":"Thode AR, Latkany RA. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD). Drugs. 2015;75:1177\u201385.","journal-title":"Drugs"},{"key":"906_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","volume":"56","author":"F Lallemand","year":"2003","unstructured":"Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307\u201318.","journal-title":"Eur J Pharm Biopharm"},{"key":"906_CR9","doi-asserted-by":"crossref","unstructured":"Bang SP, Yeon CY, Adhikari N, Neupane S, Kim H, Lee DC, et al. Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model. PLoS One 2019;14:e0224805.","DOI":"10.1371\/journal.pone.0224805"},{"key":"906_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","volume":"117","author":"F Lallemand","year":"2017","unstructured":"Lallemand F, Schmitt M, Bourges JL, Gurny R, Benita S, Garrigue JS. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14\u201328.","journal-title":"Eur J Pharm Biopharm"},{"key":"906_CR11","doi-asserted-by":"crossref","unstructured":"Yang S, Byun Y-S, Rho CR, Kim SY, Cho YK, Kim EC, et al. Comparisons for evaluation of efficacy and safety of cyclosporin a 0.05% ophthalmic emulsion treatment groups. Journal of the Korean Ophthalmological Society 2016;57:1849\u201356.","DOI":"10.3341\/jkos.2016.57.12.1849"},{"key":"906_CR12","doi-asserted-by":"crossref","unstructured":"Kang MJ, Kim YH, Chou M, Hwang J, Cheon EJ, Lee HJ, et al. Evaluation of the efficacy and safety of a novel 0.05% cyclosporin A topical nanoemulsion in primary Sj\u00f6gren's syndrome dry eye. Ocul Immunol Inflamm 2020;28:370\u20138.","DOI":"10.1080\/09273948.2019.1587470"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3341\/kjo.2018.0104","volume":"33","author":"Y Eom","year":"2019","unstructured":"Eom Y, Na KS, Cho KJ, Hwang HS, Kim SW, Chung TY, et al. Distribution and characteristics of meibomian gland dysfunction subtypes: a multicenter study in South Korea. Korean J Ophthalmol. 2019;33:205\u201313.","journal-title":"Korean J Ophthalmol"},{"key":"906_CR14","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1167\/iovs.11-9228","volume":"53","author":"E Viso","year":"2012","unstructured":"Viso E, Rodr\u00edguez-Ares MT, Abelenda D, Oubi\u00f1a B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci. 2012;53:2601\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"906_CR15","doi-asserted-by":"publisher","first-page":"11796","DOI":"10.1038\/s41598-020-67888-5","volume":"10","author":"Y Eom","year":"2020","unstructured":"Eom Y, Na KS, Hwang HS, Cho KJ, Chung TY, Jun RM, et al. Clinical efficacy of eyelid hygiene in blepharitis and meibomian gland dysfunction after cataract surgery: a randomized controlled pilot trial. Sci Rep. 2020;10:11796.","journal-title":"Sci Rep"},{"key":"906_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jtos.2016.09.003","volume":"15","author":"K Tsubota","year":"2017","unstructured":"Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society. Ocul Surf. 2017;15:65\u201376.","journal-title":"Ocul Surf"},{"key":"906_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10384-020-00803-7","volume":"65","author":"Y Eom","year":"2021","unstructured":"Eom Y, Hyon JY, Lee HK, Song JS, Kim HM. A multicenter cross-sectional survey of dry eye clinical characteristics and practice patterns in Korea: the DECS-K study. Jpn J Ophthalmol. 2021;65:261\u201370.","journal-title":"Jpn J Ophthalmol"},{"key":"906_CR18","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.18240\/ijo.2021.10.07","volume":"14","author":"Y Eom","year":"2021","unstructured":"Eom Y, Kim HM. Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study. Int J Ophthalmol. 2021;14:1518\u201326.","journal-title":"Int J Ophthalmol"},{"key":"906_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clae.2015.01.005","volume":"38","author":"Z Lacroix","year":"2015","unstructured":"Lacroix Z, L\u00e9ger S, Bitton E. Ex vivo heat retention of different eyelid warming masks. Cont Lens Anterior Eye. 2015;38:152\u20136.","journal-title":"Cont Lens Anterior Eye"},{"key":"906_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.clae.2019.09.005","volume":"42","author":"AA Tichenor","year":"2019","unstructured":"Tichenor AA, Cox SM, Ziemanski JF, Ngo W, Karpecki PM, Nichols KK, et al. Effect of the Bruder moist heat eye compress on contact lens discomfort in contact lens wearers: An open-label randomized clinical trial. Cont Lens Anterior Eye. 2019;42:625\u201332.","journal-title":"Cont Lens Anterior Eye"},{"key":"906_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","volume":"25","author":"J Luchs","year":"2008","unstructured":"Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25:858\u201370.","journal-title":"Adv Ther"},{"key":"906_CR22","doi-asserted-by":"crossref","unstructured":"Fadlallah A, Rami HE, Fahd D, Dunia I, Bejjani R, Chlela E, et al. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq Bras Oftalmol 2012;75:178\u201382.","DOI":"10.1590\/S0004-27492012000300006"},{"key":"906_CR23","unstructured":"Efron, Nathan (2000) Efron grading scales for contact lens complications (Millennium Edition), Butterworth-Heinemann. Available at: https:\/\/eprints.qut.edu.au\/11857\/1\/11857a.pdf. Accessed 22 Dec 2020."},{"key":"906_CR24","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","volume":"52","author":"A Tomlinson","year":"2011","unstructured":"Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006\u201349.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"906_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1542-0124(12)70139-8","volume":"1","author":"GN Foulks","year":"2003","unstructured":"Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1:107\u201326.","journal-title":"Ocul Surf"},{"key":"906_CR26","doi-asserted-by":"crossref","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171\u20135.","DOI":"10.1097\/01.ico.0000176611.88579.0a"},{"key":"906_CR27","doi-asserted-by":"crossref","unstructured":"Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea 2012;31:1386\u201393.","DOI":"10.1097\/ICO.0b013e31823cc098"},{"key":"906_CR28","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/j.1600-6143.2007.01881.x","volume":"7","author":"HG Kang","year":"2007","unstructured":"Kang HG, Zhang D, Degauque N, Mariat C, Alexopoulos S, Zheng XX. Effects of cyclosporine on transplant tolerance: the role of IL-2. Am J Transplant. 2007;7:1907\u201316.","journal-title":"Am J Transplant"},{"key":"906_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807\u201315.","journal-title":"Cell"},{"key":"906_CR30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","volume":"126","author":"HD Perry","year":"2008","unstructured":"Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, Greenman HE, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126:1046\u201350.","journal-title":"Arch Ophthalmol"},{"key":"906_CR31","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1167\/iovs.10-6997c","volume":"52","author":"E Knop","year":"2011","unstructured":"Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52:1938\u201378.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"906_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/ICO.0000000000001460","volume":"37","author":"Y Eom","year":"2018","unstructured":"Eom Y, Han JY, Kang B, Hwang HS, Lee HK, Kim HM, et al. Meibomian glands and ocular surface changes after closure of meibomian gland orifices in rabbits. Cornea. 2018;37:218\u201326.","journal-title":"Cornea"},{"key":"906_CR33","unstructured":"Reyes N, Saban DRJIO, Science V. Pathogenesis of meibomian gland dysfunction (MGD) requires the T cell-neutrophil axis, in the allergy setting. 2016;57:1431."},{"key":"906_CR34","unstructured":"Kim HY, Lee JE, Oh HN, Song JW, Han SY, Lee JS. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. Int J Ophthalmol 2018;11:593\u2013600."},{"key":"906_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00347-009-2044-8","volume":"106","author":"E Knop","year":"2009","unstructured":"Knop E. Knop N [Meibomian glands\u202f: part IV. Functional interactions in the pathogenesis of meibomian gland dysfunction (MGD)]. Ophthalmologe. 2009;106:980\u20137.","journal-title":"Ophthalmologe"},{"key":"906_CR36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jtos.2017.03.005","volume":"15","author":"S Fukuoka","year":"2017","unstructured":"Fukuoka S, Arita R. Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes. Ocul Surf. 2017;15:730\u20135.","journal-title":"Ocul Surf"},{"key":"906_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/bjophthalmol-2012-302668","volume":"97","author":"R Arita","year":"2013","unstructured":"Arita R, Suehiro J, Haraguchi T, Maeda S, Maeda K, Tokoro H, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2013;97:725\u20139.","journal-title":"Br J Ophthalmol"},{"key":"906_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/bjophthalmol-2016-310097","volume":"102","author":"SL Maskin","year":"2018","unstructured":"Maskin SL, Testa WR. Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2018;102:59\u201368.","journal-title":"Br J Ophthalmol"},{"key":"906_CR39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802\u201312.","journal-title":"Ocul Surf"},{"key":"906_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.survophthal.2009.02.002","volume":"54","author":"E Donnenfeld","year":"2009","unstructured":"Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321\u201338.","journal-title":"Surv Ophthalmol"},{"key":"906_CR41","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1136\/bjophthalmol-2014-305220","volume":"98","author":"PS Bilkhu","year":"2014","unstructured":"Bilkhu PS, Naroo SA, Wolffsohn JS. Randomised masked clinical trial of the MGDRx EyeBag for the treatment of meibomian gland dysfunction-related evaporative dry eye. Br J Ophthalmol. 2014;98:1707\u201311.","journal-title":"Br J Ophthalmol"},{"key":"906_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.optom.2018.07.002","volume":"12","author":"W Ngo","year":"2019","unstructured":"Ngo W, Srinivasan S, Jones L. An eyelid warming device for the management of meibomian gland dysfunction. J Optom. 2019;12:120\u201330.","journal-title":"J Optom"},{"key":"906_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10792-014-9947-3","volume":"35","author":"E Villani","year":"2015","unstructured":"Villani E, Garoli E, Canton V, Pichi F, Nucci P, Ratiglia R. Evaluation of a novel eyelid-warming device in meibomian gland dysfunction unresponsive to traditional warm compress treatment: an in vivo confocal study. Int Ophthalmol. 2015;35:319\u201323.","journal-title":"Int Ophthalmol"},{"key":"906_CR44","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1089\/jop.2016.0164","volume":"33","author":"HS Kim","year":"2017","unstructured":"Kim HS, Kim TI, Kim JH, Yoon KC, Hyon JY, Shin KU, et al. Evaluation of clinical efficacy and safety of a novel cyclosporin A nanoemulsion in the treatment of dry eye syndrome. J Ocul Pharmacol Ther. 2017;33:530\u20138.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00906-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-022-00906-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-022-00906-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T05:31:15Z","timestamp":1674883875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-022-00906-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s10384-022-00906-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,2]]},"assertion":[{"value":"3 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J. W. Rhim, None; Y. Eom, None; E. G. Yoon, None; S. Y. Park, None; Y. Choi, None; J. S. Song, None; H. M. Kim, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}